awmsg logo



icatibant acetate (Firazyr®)


Reference No. 907

Publication date:
08/03/2012


Last review date:
30/09/2016

Appraisal information

icatibant acetate (Firazyr®) 30 mg solution for injection


Company: Shire Human Genetic Therapies
BNF category: Respiratory system
NMG meeting date: 04/01/2012
AWMSG meeting date: 08/02/2012
   
   
Submission Type: Resubmission
Status: Recommended
Advice No: 0512
Ministerial ratification: 08/03/2012

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Icatibant (Firazyr®) is recommended as an option for use within NHS Wales for the symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1 esterase inhibitor deficiency). This recommendation applies only in circumstances where the approved Wales patient access scheme is utilised. AWMSG is of the opinion that icatibant (Firazyr®) is suitable for specialist only prescribing within NHS Wales for the above indication.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download